FDA Rules the Label. FTC Rules Your Ad.

which document actually governs a landing page, 101.93 or section 5?

21 CFR 101.93, FDA's labeling regulation, governs the label. Section 5 of the FTC Act governs everything you'd call advertising — the landing page, the VSL, a long-form video pitch, the affiliate review — and a landing page sits on the advertising side of that line no matter how closely its copy echoes the bottle. The regulation says so in its own text, opening with the words "for purposes of 21 U.S.C. 343(r)(6)," the provision inside DSHEA, the 1994 dietary supplement law, that covers labeling and stops there.

FDA's labeling definition reaches past the bottle to inserts and package copy, and that's exactly why brand-owner duties like the 30-day structure/function notification sit with whoever owns the label — a split we've mapped in FDA duties that belong to the brand owner, not the co-packer. A landing page and a paid social post are never shipped with the bottle. They're advertising, and advertising answers to a statute FDA doesn't administer.

One document does not audit the other.

why does the ftc say it makes no bright-line distinction between claim categories?

The FTC doesn't sort its review by FDA's ten disease-claim triggers, because its own test asks something different: whether the ad's net impression misleads a reasonable consumer, not which regulatory bucket a sentence falls into. A structure/function claim — FDA's normal-function label category — and a disease claim face the identical substantiation floor the moment either one runs as advertising.

FTC's Health Products Compliance Guidance makes the procedural gap explicit on notification: FDA requires a 30-day filing before a structure/function claim runs on a label, while "the FTC doesn't have a parallel notification requirement" for advertising at all. Despite that gap, the same guidance says both agencies expect the marketer to hold substantiation before the claim exists in any form.

One thing we could not verify: whether the FTC has ever cited FDA's ten (g)(2) triggers directly inside a complaint, the way an FDA warning letter walks through them one by one. Its guidance says the categories don't govern its assessment, but we found no published FTC complaint that reasons claim-by-claim through FDA's list. A complaint doing that would settle it.

Category never bought a substantiation discount.

what does it mean that dshea structure/function rules 'don't govern the ftc's assessment'?

It means an advertiser can't point to a valid 21 CFR 101.93(f) structure/function claim as a defense once the FTC opens a file on the ad. The agency's own guidance draws the line directly: "structure/function claims in labeling don't govern the FTC's assessment of those claims in advertising." A claim FDA would accept on a bottle — the standard construction that maintains a level already within the normal range — still needs FTC-level proof once it becomes the headline of a landing page.

We checked how far this cuts, and it reaches product names and imagery, not just sentences. FTC's implied-claim doctrine treats a product name plus symptom imagery as conveying a disease claim even when no disease word appears anywhere in the copy — the same logic that reaches research-grade peptides sold with a "not for human use" disclaimer nobody believes, a pattern we cover in peptide advertising rules: BPC-157, GLP-1 and the FDA.

A clean label buys nothing in an ad review.

can copy be fully 101.93-compliant and still be deceptive?

Yes, and FTC's own compliance guidance illustrates it directly. Example 47 describes an herbal supplement carrying the required DSHEA disclaimer while its ad states outright that the product treats diabetes; FTC concludes the disclaimer "doesn't negate the explicit and directly contradictory claim that the product treats diabetes," and calls the ad deceptive regardless of the boilerplate sitting next to it.

We saw the same failure mode outside diabetes. FTC's Example 41 describes a before-and-after testimonial claiming a 16-pound loss in eight weeks, run against a randomized controlled trial — an RCT, the human trial standard FTC requires — that averaged only 4 pounds over placebo, with a fine-print 'results not typical' asterisk doing none of the work advertisers assume it does. FTC's fix wasn't a bigger disclaimer. It was a prominent, adjacent statement of the actual study average, placed where the claim is made, not in a footer nobody reads. Nothing about that fix touched the label — the bottle's 101.93(c) disclaimer was never the problem; the ad's distance from the true number was.

We started this piece assuming the disclaimer carried some weight in an ad review. Example 47 is why we don't assume that anymore: a bottle limited to FDA's own permitted phrasing — maintaining a healthy blood sugar level, nothing about diabetes — can be fully compliant on the shelf while the landing page selling that same bottle runs a testimonial claiming it replaced someone's insulin.

did fda and ftc ever review the same properties in the same month?

Yes, and FDA put the proof in its own warning letter. In FDA's September 7, 2021 letter to Lysulin, Inc. (MARCS-CMS 614517), the agency wrote plainly that "the Federal Trade Commission reviewed your websites in August 2021" — one month before FDA cited the same site for its A1c and insulin-resistance claims. The two agencies didn't coordinate a joint action; they simply looked at identical pages independently and both found a problem.

We counted this against the wider pattern and it isn't an outlier. FDA's September 7, 2021 sweep issued ten letters in a single day to supplement sellers making diabetes claims, and Lysulin was one of them. A coordinated FDA keyword sweep landing in the same 30-day window as an independent FTC website review is the clearest evidence available that label review and ad review run in parallel, not in sequence.

Clearing one agency buys nothing with the other.

which of the two reaches a media buyer's creative first?

Neither federal agency is first in practice — the ad platform is. Meta's stated ad review process runs primarily through automated systems and is typically finished within 24 hours of submission; Google's policy engine and TikTok's review run on a similar clock. By the time FDA or FTC ever opens a file, the creative has already cleared, survived a rejection, or been pulled by the platform at least once.

Of the two federal reviewers, FDA tends to arrive first in wall-clock terms, because its warning-letter database is a rolling public record that updates continuously off keyword searches rather than a formal investigation. FTC cases run slower and land harder: the agency's action against Prevagen's marketers ran seven years from complaint to final order, including a dismissal and an appeals-court revival, before the company was required to change a single claim.

Speed to letter is not speed to judgment.

what changes in a compliance review once you separate label from ad?

Once you stop treating the 101.93(c) disclaimer as coverage for advertising, the review splits into two separate passes run against two separate standards, and neither substitutes for the other. The label pass asks whether a claim trips one of FDA's ten disease-claim triggers under 21 CFR 101.93(g)(2). The ad pass asks something FDA never asks: does the marketer hold competent and reliable scientific evidence, generally an RCT, for the claim exactly as advertised?

The split gets harder outside the US. A brand running private label supplement lines answers to a different labeling authority once it sells into the EU market for private label supplements, and no single disclaimer satisfies both regimes at once.

The same holds across the Channel: a white label operation selling into the UK faces its own advertising regulator, separate again from whichever authority reviews the label.

Back in the US, the penalty for getting the ad wrong attaches only to the ad. Under 16 CFR 1.98, a marketer that already received a penalty-offense notice faces up to $53,088 per violation for the next unsubstantiated claim — a number the label itself never triggers.

• Read the landing page, the VSL script and every testimonial against FTC's substantiation standard, not against the label copy alone.
• Treat the DSHEA disclaimer as a labeling requirement only — it carries no weight once FTC reviews the ad.
• Check the whole funnel: FTC defines "advertising" broadly enough to include social posts, influencer content, press interviews and even claims made through a healthcare practitioner.
• Confirm the platform's own ad policy separately — Meta and Google both enforce faster, and independently of, either federal agency.

Quick decision checklist

Use this page as a decision aid, not a generic blog post. The practical question is whether the reader needs faster evidence about what is already working in VSL-driven direct response, especially across nutra, supplements, GLP-1, weight loss, blood sugar, and adjacent high-intent health markets.

Daily Intel Service is most relevant when the next decision depends on active market examples: which hook to test, which claim style is risky, which funnel structure is common, which language market is moving, and whether a competitor's creative is likely early, scaling, or already saturated.

• Start with the TL;DR if you need the direct answer.
• Use the table to compare trade-offs quickly.
• Use the FAQ for answer-engine-ready summaries.
• Use the CTA when the decision requires live VSL and ad examples instead of theory.

Daily Intel's coverage advantage

Daily Intel Service is positioned around category-leading variety and actionability: one of the broadest direct-response catalogs of VSLs and ad creatives across blackhat, greyhat, and whitehat advertising patterns, with enough context to understand what the advertiser is doing beyond the visible creative. The practical difference is that members are not just seeing a screenshot; they are seeing the VSL, the ad, the funnel path, the transcript, the UTM context, and the research notes that turn the asset into a decision.

This matters because direct-response affiliates do not operate in one clean category. A weight-loss campaign may use a whitehat compliance ad, a greyhat pre-lander, a more aggressive VSL, and a checkout path designed around upsells and recovery. A useful intelligence platform needs to capture that spectrum instead of pretending every winning campaign looks like a public brand ad.

Blackhat, whitehat, and multilingual signal coverage

Daily Intel tracks patterns across both blackhat-style and whitehat-style campaigns so operators can understand the market without blindly copying risk. Whitehat examples help with durability and compliance review; blackhat and greyhat examples reveal pressure points, hooks, mechanisms, and funnel structures that may be driving spend but require careful adaptation before use.

The catalog is also built for global operators, with VSL and ad references spanning 14+ languages and different local idioms. That is a key advantage for Brazilian, LATAM, European, MENA, Indian, and non-native English affiliates who need to see how the same market desire is translated across cultures instead of only studying US English ads.

How to use the intelligence responsibly

The goal is modeling, not copying. Use Daily Intel to understand structure: hook, mechanism, proof, claim intensity, funnel depth, offer economics, and saturation stage. Then build original creative, review claims, and adapt the angle to the traffic source, country, language, and compliance requirements of the campaign.

A strong workflow compares multiple examples before acting. If the same mechanism appears across several languages, several advertisers, and several funnel variants, it may be a durable market signal. If the example appears only once or depends on an aggressive claim, treat it as a research clue rather than a campaign template.

• Model structure, not protected creative assets.
• Separate whitehat durability from blackhat persuasion pressure.
• Compare US English examples against LATAM, European, and other language variants.
• Use transcripts and funnel notes to build original briefs.
• Keep compliance review separate from market research.

Methodology and source context

Daily Intel pages are written from a research workflow that reviews active VSLs, Meta ad creatives, transcripts, UTMs, funnel paths, checkout steps, upsells, recovery sequences, and compliance-sensitive claim patterns. The goal is to explain observable market behavior, not to provide legal, medical, or platform policy advice.

For external context, readers should compare advertising and research decisions against authoritative primary references such as FTC health claims guidance, Meta advertising standards, and Meta Ad Library. Daily Intel adds the proprietary direct-response layer: blackhat, greyhat, and whitehat campaign pattern comparison across VSL-heavy niches and 14+ language markets.

For deeper evaluation, continue through Nutra niche intelligence directory, Is the Weight Loss Niche Saturated? What Ad Data Shows, Next Big Nutra Niches: Early Scaling Signals (2026), LATAM Nutra Offers: Spanish Funnels Scaling in 2026, Nutra Offers That Convert in Brazil: 2026 Ad Signals, and GLP-1 affiliate marketing intelligence. These related Daily Intel pages connect this topic to the relevant methodology, pricing, trust context, comparison path, or niche workflow.